Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Oliver Sartor

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Clinical Advances in Hematology & Oncology : H&O|August 19, 2021
PSMA-targeted radiotherapy in metastatic castration-resistant prostate cancerA Oliver Sartor
Oncology (Williston Park, N.Y.)|August 6, 2013
Surveillance for prostate cancer: are the proceduralists running amok?A Oliver Sartor
Journal of Hematology & Oncology|April 26, 2011
Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel spaceA Oliver Sartor
BJU International|June 21, 2012
Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC)A Oliver Sartor, John M Fitzpatrick
Urologic Oncology|February 26, 2013
The current role and limitations of surrogate endpoints in advanced prostate cancerLeonard G Gomella, A Oliver Sartor
Cancer|April 2, 2019
Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or…Pedro C Barata, A Oliver Sartor
Urology|November 19, 2013
Editorial commentSandip M Prasad, A Oliver Sartor, Charles L Bennett
JAMA Oncology|July 17, 2015
Population-Based Assessment of Determining Treatments for Prostate CancerSandip M Prasad, A Oliver Sartor, Charles L Bennett
Urology|July 6, 2015
Editorial CommentSandip Prasad, Terhi Hermanson, Charles L Bennett, et al.
Urology|December 20, 2008
Prostate cancer: epidemiology and health-related quality of lifeDavid F Penson, Michel Rossignol, A Oliver Sartor, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Clinical Advances in Hematology & Oncology : H&O|August 19, 2021
PSMA-targeted radiotherapy in metastatic castration-resistant prostate cancerA Oliver Sartor
Oncology (Williston Park, N.Y.)|August 6, 2013
Surveillance for prostate cancer: are the proceduralists running amok?A Oliver Sartor
Journal of Hematology & Oncology|April 26, 2011
Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel spaceA Oliver Sartor
BJU International|June 21, 2012
Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC)A Oliver Sartor, John M Fitzpatrick
Urologic Oncology|February 26, 2013
The current role and limitations of surrogate endpoints in advanced prostate cancerLeonard G Gomella, A Oliver Sartor
Cancer|April 2, 2019
Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or…Pedro C Barata, A Oliver Sartor
Urology|November 19, 2013
Editorial commentSandip M Prasad, A Oliver Sartor, Charles L Bennett
JAMA Oncology|July 17, 2015
Population-Based Assessment of Determining Treatments for Prostate CancerSandip M Prasad, A Oliver Sartor, Charles L Bennett
Urology|July 6, 2015
Editorial CommentSandip Prasad, Terhi Hermanson, Charles L Bennett, et al.
Urology|December 20, 2008
Prostate cancer: epidemiology and health-related quality of lifeDavid F Penson, Michel Rossignol, A Oliver Sartor, et al.
Pageof 5